Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1240-1243

  Green, Michael D ^a   Beall, Bernard ^b   Marcon, Mario J ^c   Allen, Coburn H ^d   Bradley, John S ^e   Dashefsky, Barry ^f   Gilsdorf, Janet R ^g   Schutze, Gordon E ^h   Smith, Clay ⁱ   Walter, Emmanuel B ^j   Martin, Judith M ^a   Edwards, Kathryn M ⁱ   Barbadora, Karen A ^a   Wald, Ellen R ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h ARKANSAS CHILDREN S HOSPITAL   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Antibiotic resistance; Mef (A); Streptococcus pyogenes

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; ENDODEOXYRIBONUCLEASE APAI; ERMTR PROTEIN, BACTERIA; MEFA PROTEIN, STREPTOCOCCUS; MEMBRANE PROTEIN; METHYLTRANSFERASE; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DIFFUSION; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; LONGITUDINAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PHARYNX; PHENOTYPE; PREVALENCE; STREPTOCOCCUS GROUP A; UNITED STATES; CLASSIFICATION; CLINICAL TRIAL; DNA FINGERPRINTING; DRUG EFFECT; EPIDEMIOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; EPIDEMIOLOGY, MOLECULAR; HUMANS; MACROLIDES; MEMBRANE PROTEINS; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; PHARYNX; POLYMERASE CHAIN REACTION; PREVALENCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; UNITED STATES;

EID: 33749005569     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl101     Document Type: Article

References (14)

1. Bassetti M, Manno G, Collida A et al. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis 2000; 6: 180-3.
2. Freeman AF, Shulman ST. Macrolide resistance in group A Streptococcus. Pediatr Infect Dis J 2002; 21: 1158-60.
3. Martin JM, Green M, Barbadora KA et al. Erythromycin-resistant group A streptococci in school children in Pittsburgh. N Engl J Med 2002; 346: 1200-6.
4. Green M, Martin JM, Barbadora KA et al. Reemergence of macrolide resistance in pharyngeal isolates of group A streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother 2004; 48: 473-6.
5. National Committee for Clinical Laboratory Standards. Performance Standards for Susceptibility Testing: Tenth Informational Supplement M100-S10 (M7). NCCLS, Wayne, PA, USA, 2000.
6. Green M, Allen C, Bradley J et al. In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States. Antimicrob Agents Chemother 2005; 49: 2487-9.
7. Li Z, Sakota V, Jackson D et al. Array of M protein gene subtypes in 1064 recent invasive group A streptococcus isolates recovered from the active bacterial core surveillance. J Infect Dis 2003; 188: 1587-92.
8. Farrell DJ, Shackcloth J, Barbadora KA et al. Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations. Antimicrob Agents Chemother 2006; 50: 817-8.
9. Critchley IA, Sahm DF, Thornsberry C et al. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis 2002; 42: 129-35.
10. Barrozo CP, Russell KL, Smith TC et al. National Department of Defense surveillance data for antibiotic resistance and emm gene types of clinical group A streptococcal isolates from eight basic training military sites. J Clin Microbiol 2003; 41: 4808-11.
11. Richter SS, Heilmann KP, Beekmann SE et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41: 599-608.
12. Tanz RR, Shulman ST, Shortridge VD et al. Community-based surveillance in the United States of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis 2004; 39: 1794-801.
13. Banks DJ, Porcella SF, Barbian KD et al. Structure and distribution of an unusual chimeric genetic element encoding macrolide resistance in phylogenetically diverse clones of group A Streptococcus. J Infect Dis 2003; 188: 1898-908.
14. Cresti S, Lattanzi M, Zanchi A et al. Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance. Antimicrob Agents Chemother 2002; 46: 1816-22.